Literature DB >> 28867125

Comparison of Benefit of Successful Percutaneous Coronary Intervention for Chronic Total Occlusion in Patients With Versus Without Reduced (≤40%) Left Ventricular Ejection Fraction.

Aurel Toma1, Barbara E Stähli2, Michael Gick3, Catherine Gebhard3, Beat A Kaufmann3, Kambis Mashayekhi3, Miroslaw Ferenc3, Heinz Joachim Buettner3, Franz-Josef Neumann3.   

Abstract

Successful recanalization of chronic total occlusions (CTO) has been associated with improved survival. Data on outcomes in patients with left ventricular (LV) systolic dysfunction undergoing percutaneous coronary intervention for CTO, however, are scarce. Between January 2005 and December 2013, a total of 2,002 consecutive patients undergoing elective CTO percutaneous coronary intervention at a tertiary care center were divided into patients with (LV ejection fraction ≤ 40%) and without (LV ejection fraction > 40%) LV systolic dysfunction as defined by transthoracic echocardiography. The primary end point was all-cause mortality. Median follow-up was 2.6 (1.1 to 3.1) years. A total of 348 (17.4%) patients had LV dysfunction. All-cause mortality was higher in patients with LV dysfunction (30.2%) than in those with normal LV function (8.2%, p <0.001), and associations remained significant after adjustment for baseline differences (adjusted hazard ratio [HR] 3.39, 95% confidence interval [CI] 2.57 to 4.47, p <0.001). Successful CTO recanalization was independently associated with reduced all-cause mortality, with similar relative risk reductions in both the preserved (6.6% vs 16.9%, adjusted HR 0.48, 95% CI 0.34 to 0.70, p <0.001) and the reduced LV function groups (26.2% vs 45.2%, adjusted HR 0.63, 95% CI 0.41 to 0.98, p = 0.04, interaction p = 0.28). In conclusion, irrespective of LV function, successful CTO recanalization is associated with a clear survival benefit.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28867125     DOI: 10.1016/j.amjcard.2017.07.088

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Quantitative coronary computed tomography angiography assessment of chronic total occlusion percutaneous coronary intervention.

Authors:  Haoran Xing; Lijun Zhang; Dongfeng Zhang; Rui Wang; Jinfan Tian; Yinghui Le; Zhiguo Ju; Hui Chen; Yi He; Xiantao Song
Journal:  Quant Imaging Med Surg       Date:  2022-07

Review 2.  Role of Percutaneous Chronic Total Occlusion Interventions in Patients with Ischemic Cardiomyopathy and Reduced Left Ventricular Ejection Fraction.

Authors:  Nayef A Abouzaki; Jose E Exaire; Luis A Guzmán
Journal:  Curr Cardiol Rep       Date:  2018-10-01       Impact factor: 2.931

3.  Myocardial Viability, Functional Status, and Collaterals of Patients With Chronically Occluded Coronary Arteries.

Authors:  Xueyao Yang; Jinfan Tian; Lijun Zhang; Wei Dong; Hongzhi Mi; Jianan Li; Jiahui Li; Ye Han; Huijuan Zuo; Jing An; Yi He; Xiantao Song
Journal:  Front Cardiovasc Med       Date:  2021-11-12

4.  Development and Validation of a Novel Nomogram to Predict Improved Left Ventricular Ejection Fraction in Patients With Heart Failure After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion.

Authors:  Lulu Yang; Huan Li; Guangli Guo; Jiaqi Du; Zhengyang Hao; Lingyao Kong; Huiting Shi; Xiaofang Wang; Yanzhou Zhang
Journal:  Front Cardiovasc Med       Date:  2022-04-14

5.  Left Main Coronary Artery Disease and Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions.

Authors:  Max-Paul Winter; Georg Goliasch; Philipp Bartko; Jolanta Siller-Matula; Mohamed Ayoub; Stefan Aschauer; Klaus Distelmaier; Catherine Gebhard; Kambis Mashayekhi; Miroslaw Ferenc; Christian Hengstenberg; Aurel Toma
Journal:  J Clin Med       Date:  2020-03-30       Impact factor: 4.241

6.  Scoring System for Identification of "Survival Advantage" after Successful Percutaneous Coronary Intervention in Patients with Chronic Total Occlusion.

Authors:  Tatsuya Nakachi; Shun Kohsaka; Masahisa Yamane; Toshiya Muramatsu; Atsunori Okamura; Yoshifumi Kashima; Shunsuke Matsuno; Masami Sakurada; Yoshitane Seino; Maoto Habara
Journal:  J Clin Med       Date:  2020-05-02       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.